<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Med Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J. Med. Res</journal-id>
      <journal-id journal-id-type="publisher-id">IJMR</journal-id>
      <journal-title-group>
        <journal-title>The Indian Journal of Medical Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0971-5916</issn>
      <issn pub-type="epub">0975-9174</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25900964</article-id>
      <article-id pub-id-type="pmc">4418166</article-id>
      <article-id pub-id-type="publisher-id">IJMR-141-247</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Images</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Herpes zoster complicating bortezomib therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sahu</surname>
            <given-names>Kamal Kant</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Varma</surname>
            <given-names>Subhash Chander</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">Clinical Hematology Department of Internal Medicine Postgraduate Institute of Medical Education &amp; Research, Chandigarh 160 012, India</aff>
      <author-notes>
        <corresp id="cor1">
          <label>*</label>
          <italic>For correspondence:</italic>
          <email xlink:href="hematpgi@gmail.com">hematpgi@gmail.com</email>
        </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2015</year>
      </pub-date>
      <volume>141</volume>
      <issue>2</issue>
      <fpage>247</fpage>
      <lpage>248</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Medical Research</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>A 62 year old female patient with multiple myeloma was on follow up in the Haematology clinic, department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, and was receiving bortezomib based chemotherapy given on days 1, 4, 8, and 11 of 35-day cycle. After two such cycles in June 2013, she started developing painful skin lesions on right D9-10 dermatome. On examination erythematous, crusted superficial erosions with a few vesicular lesions were present (Figs <xref ref-type="fig" rid="F1">A</xref>, <xref ref-type="fig" rid="F1">B</xref>). Tzanck smear showed multinucleated giant cells confirming the diagnosis of herpes zoster (Figs <xref ref-type="fig" rid="F1">C</xref>, <xref ref-type="fig" rid="F1">D</xref>). It was found that despite advice she did not take acyclovir prophylaxis during chemotherapy which led to this complication. She was given oral valganciclovir 1 g thrice a day for 10 days. Unfortunately, she was lost to follow up. There are theories which explain increased susceptibility of patients on bortezomib to herpes infection<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>. Considering two earlier studies<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref> and our case, it is emphasised that acyclovir prophylaxis should be used during bortezomib treatment.</p>
    <fig id="F1" position="float">
      <label>Figs</label>
      <caption>
        <p><bold>A, B.</bold> Well defined erythematous, crusted erosions with a few vesicular lesions (indicated by black arrows in <bold>(B)</bold> in a linear pattern over the right D 9-10 dermatome. <bold>Figs C, D.</bold> Light microscopy using tzanck smear and stained with Wright-Giemsa stain showing giant cells.</p>
      </caption>
      <graphic xlink:href="IJMR-141-247-g001"/>
    </fig>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swaika</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Paulus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Sher</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Almyroudis</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Ball</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients</article-title>
          <source>J Support Oncol</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>155</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">22222250</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Argyriou</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Iconomou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kalofonos</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>112</volume>
          <fpage>1593</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">18574024</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vickrey</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Singhal</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy</article-title>
          <source>Cancer</source>
          <year>2009</year>
          <volume>115</volume>
          <fpage>229</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">19090004</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aoki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishiyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Imahashi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2011</year>
          <volume>41</volume>
          <fpage>876</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">21616919</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
